Verrica製藥 VRCA 深 滬
等待開盤 09-24 09:30:00 美东时间
4.62
-0.100
-2.12%
華盛通- 最 高4.78
- 今 開4.67
- 成交量 4.13万股
- 最 低 4.55
- 昨 收 4.72
- 總市值 7936.60万
- 52周最高 9.8212
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 3.28
- 委 比 54.02%
- 總股本 1717.88万
- 歷史最高 232.90
- 量 比 0.69
- 振 幅 4.87%
- 歷史最低 3.816
- 每 手 1
- 風險率 1.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Verrica Pharmaceuticals Inc. announced that its CEO, Jayson Rieger, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, in New York. The event will be live webcast and available for replay on the company's website. Verrica specializes in developing treatments for dermatological diseases, including skin cancers, with its product YCANTH® (VP-102) approved for molluscum contagiosum and under developmen...
09-08 12:00
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
Verrica Pharmaceuticals announced the completion of enrollment in the first pivotal Phase 3 trial (COVE-2) for YCANTH® (VP-102) in treating common warts. An interim analysis confirmed no additional patients are needed for full enrollment. The second trial (COVE-3) has exceeded 50% of its target enrollment and is expected to provide top-line data by mid-2027. YCANTH has the potential to become the first FDA-approved prescription drug for common wa...
08-27 12:00
Verrica Pharmaceuticals Earnings Call: Growth Amid Losses
Verrica Pharmaceuticals (($VRCA)) has held its Q2 earnings call. Read on for th...
08-22 08:26
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 292 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $5.862...
08-07 04:08
Verrica 2026年第二季度财报：YCANTH增长但研发支出扩大亏损
Verrica（VRCA）2026年第二季度营收586.2万美元，同比下降53.9%；YCANTH美国收入增长12.3%至509.3万美元，GAAP净亏损扩大至1,315.3万美元。
08-06 22:10
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
<p>Verrica Pharmaceuticals Inc. will host a conference call and live webcast on August 6, 2026, at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and provide a corporate update. Participants can join via phone by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) using conference ID: VERRICA, or via webcast on the company’s website. Verrica, a therapeutics company focused on dermatological diseases, including s...
07-30 12:00
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones
Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maintain marketing authorizations for YCANTH in Israel. Verrica will manufacture YCANTH and provide commercial supply to Medomie and will receive 60% of the net selling price of product sold by Medomie in ...
07-21 20:07
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Verrica Pharmaceuticals Inc. has entered an exclusive agreement with Medomie Pharma Ltd. to distribute YCANTH® for molluscum contagiosum in Israel. Verrica will manufacture the product and receive 60% of net sales, plus up to $8.2 million in milestones. YCANTH, the first FDA-approved treatment for molluscum, is now also approved in Japan and under study for common warts. Verrica retains global rights outside Japan and Israel.
07-21 12:00
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy rating and announces Price Target of $12.
05-26 18:51
